In the last trading session, 1.83 million shares of the Lucid Diagnostics Inc (NASDAQ:LUCD) were traded, and its beta was 1.27. Most recently the company’s share price was $1.50, and it changed around -$0.02 or -1.32% from the last close, which brings the market valuation of the company to $125.45M. LUCD currently trades at a discount to its 52-week high of $1.63, offering almost -8.67% off that amount. The share price’s 52-week low was $0.63, which indicates that the current value has risen by an impressive 58.0% since then. We note from Lucid Diagnostics Inc’s average daily trading volume that its 10-day average is 0.94 million shares, with the 3-month average coming to 593.80K.
Lucid Diagnostics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 6 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 0 recommended LUCD as a Hold, whereas 4 deemed it a Buy, and 0 rated it as Underweight. Lucid Diagnostics Inc is expected to report earnings per share of -0.13 for the current quarter.
Lucid Diagnostics Inc (NASDAQ:LUCD) trade information
Instantly LUCD has showed a red trend with a performance of -1.32% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 1.6000 on recent trading dayincreased the stock’s daily price by 6.25%. The company’s shares are currently up 83.22% year-to-date, but still up 2.04% over the last five days. On the other hand, Lucid Diagnostics Inc (NASDAQ:LUCD) is 2.74% up in the 30-day period. We can see from the shorts that 1.79 million shares have been sold at a short interest cover period of 2.44 day(s).
The consensus price target as assigned by Wall Street analysts is $2.5, which translates to bulls needing to increase their stock price by 40.0% from its current value. Analyst projections state that LUCD is forecast to be at a low of $2.5 and a high of $2.5.
Lucid Diagnostics Inc (LUCD) estimates and forecasts
The year-over-year growth rate is expected to be 74.86%, up from the previous year.
Consensus estimates provided by 2 financial analysts predict the company will bring in an average of 1.25M in revenue for the current quarter. 2 analysts expect Lucid Diagnostics Inc to make 1.45M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 1M and 976k respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 24.88%. Forecasts for the next quarter put sales growth at 48.57%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -110.66%. Lucid Diagnostics Inc earnings are expected to increase by 44.94% in 2025, but the outlook is positive 40.08% per year for the next five years.
Lucid Diagnostics Inc (NASDAQ:LUCD)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 45.27% of Lucid Diagnostics Inc shares, and 5.40% of them are in the hands of institutional investors. The stock currently has a share float of 9.86%. Lucid Diagnostics Inc stock is held by 37.0 institutions, with LUMINUS MANAGEMENT LLC being the largest institutional investor. By 2024-06-30, it held 1.6124% of the shares, which is about 0.73 million shares worth $0.6 million.
VANGUARD GROUP INC, with 1.2461% or 0.56 million shares worth $0.46 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund were the top two Mutual Funds as of Dec 31, 2024 . The former held 366.92 shares worth $0.55 million, making up 0.62% of all outstanding shares. On the other hand, Vanguard Extended Market Index Fund held roughly 193.99 shares worth around $0.29 million, which represents about 0.33% of the total shares outstanding.
